Search Results | Blood | American Society of Hematology

1-20 of 711

Sort by

Sort Order Select

Journal Articles

Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy

Krishna R. Juluri, MD PhD, Alexandre V. Hirayama, MD, Erin Mullane, DNP, Nancy Cleary, BSc, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Merav Bar, MD, Jordan Gauthier, MD MSc

Blood (2019) 134 (Supplement_1): 3229.

DOI: https://doi.org/10.1182/blood-2019-126922

Published: 2019

Journal Articles

Proton Pump Inhibitors Associated with Higher Incidence of Mucositis in Patients Receiving Methotrexate for Graft Vs Host Disease Prophylaxis

Luke Mountjoy, DO, Daniel Almquist, MD, Henry Ofori, Pharm D, RPh, Marlene Girardo, MS, Margaret McCallen, Pharm D, RPh

Blood (2019) 134 (Supplement_1): 3262.

DOI: https://doi.org/10.1182/blood-2019-128644

Published: 2019

Journal Articles

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Caroline Kokulis, Jeremy M. Stewart, BA, Michael McGinnis, Lillian Werner, MS, Anthony G. Letai, MD PhD, Marina Y Konopleva, MD PhD, Marlise Luskin, MDMS

Blood (2019) 134 (Supplement_1): 3908.

DOI: https://doi.org/10.1182/blood-2019-124966

Published: 2019

Journal Articles

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Amer M. Zeidan, MBBS, MHS, Michael W. Schuster, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Magalie Joris, MD, Tobias F Menne, MD PhD FRCPath, Paresh Vyas, MD PhD, Weidong Wendy Ma, Ashleigh O'Connell, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3916.

DOI: https://doi.org/10.1182/blood-2019-124034

Published: 2019

Journal Articles

Choosing Wisely: Optimizing Outpatient Cancer Care and Conserving Resources with a New Algorithm to Report Automated ANC Results in the Presence of Analyzer Flags

Maly Fenelus, MD MPH, Ryan M Golden, MLS(ASCP), Tamiqua Graham, MLS(ASCP), Rachel J So, Jessica Lynn Bautista, BS, MT(ASCP), Ellinor I.B. Peerschke, PhD

Blood (2019) 134 (Supplement_1): 4683.

DOI: https://doi.org/10.1182/blood-2019-128963

Published: 2019

Journal Articles

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Daisuke Araki, MD, Ma Evette Barranta, Fariba Chinian, MS, Julie Erb-Alvarez, MPH, Thomas Winkler, MD, Neelam Giri, MD, Andre Larochelle, MD PhD

Blood (2019) 134 (Supplement_1): 3753.

DOI: https://doi.org/10.1182/blood-2019-123151

Published: 2019

Journal Articles

Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response

Bhavuk Garg, PhD, Hrishikesh M Mehta, PhD, Ralph Kamel, Marshall S. Horwitz, MD PhD, Seth J. Corey, MD

Blood (2019) 134 (Supplement_1): 103.

DOI: https://doi.org/10.1182/blood-2019-127409

Published: 2019

Journal Articles

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

Blood (2019) 134 (Supplement_1): 258.

DOI: https://doi.org/10.1182/blood-2019-126172

Published: 2019

Journal Articles

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Anjali S. Advani, MD, Anna Moseley, M.S., Michaela Liedtke, MD, Margaret R O'Donnell, MD, Ibrahim Aldoss, MD, Martha P. Mims, MD PhD, Kristen Marie O'Dwyer, MD, Megan Othus, PhD, Harry P. Erba, MD PhD

Blood (2019) 134 (Supplement_1): 227.

DOI: https://doi.org/10.1182/blood-2019-125340

Published: 2019

Journal Articles

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2 -Mutated Myelodysplastic Syndromes (MDS)

Guillaume Richard-Carpentier, MD, Amy E. DeZern, MD, Koichi Takahashi, MD, Marina Y Konopleva, MD PhD, Sanam Loghavi, MD, Lucia Masarova, MD, Yesid Alvarado, MD, Farhad Ravandi, MD, Guillermo Montalban Bravo, MD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Ricardo Delumpa, BSN, Monica Kwari, BSN, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD, Gail J. Roboz, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 678.

DOI: https://doi.org/10.1182/blood-2019-130501

Published: 2019

Journal Articles

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study

Scott F. Huntington, MD MPH, Avyakta Kallam, MD, Frank G. Basile, MD, Danielle Ulanet, Huansheng Xu, PhD, Feng Yin, PhD, Michelle Mobilia, BS, Michael Cooper, MD, Bijal Shah, MD, John P. Leonard, MD, Gottfried R. von Keudell, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1286.

DOI: https://doi.org/10.1182/blood-2019-123420

Published: 2019

Journal Articles

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Hassan Awada, Reda Z. Mahfouz, MD PhD, Jibran Durrani, Ashwin Kishtagari, MBBS, Deepa Jagadeesh, MDMPH, Alan Lichtin, MD, Brian T. Hill, MD, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Navneet S. Majhail, MD MS, Ronald Sobecks, MD, Valeria Visconte, PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1226.

DOI: https://doi.org/10.1182/blood-2019-130167

Published: 2019

Journal Articles

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Blood (2019) 134 (Supplement_1): 4238.

DOI: https://doi.org/10.1182/blood-2019-126967

Published: 2019

Journal Articles

Evolution of Moderate Aplastic Anemia into Subclinical PNH/AA and Successful Treatment with Reduced Intensity Haplo-HSCT: A Pediatric Case Report

Meghana Srinivas, Jennifer Krajewski, MD, Nancy Durning, APN, Melanie Hankewycz, APN, Alfred Gillio, MD

Blood (2019) 134 (Supplement_1): 5027.

DOI: https://doi.org/10.1182/blood-2019-130407

Published: 2019

Journal Articles

Effects of Hydroxyurea Treatment on Malaria Infections in Sub-Saharan Africa

Peter Olupot-Olupot, George A. Tomlinson, PhD BSc, MSc, Teresa S. Latham, MA, Patrick T. McGann, MD, Brigida Santos, Banu Aygun, MD, Susan Stuber, MA, Leon Tshilolo, MD PhD, Adam Lane, PhD, Thomas N. Williams, Russell E. Ware, MD PhD

Blood (2019) 134 (Supplement_1): 522.

DOI: https://doi.org/10.1182/blood-2019-129251

Published: 2019

Journal Articles

Thirty-Day Transfusion and G-CSF Requirement after CD19 CAR T Infusion

Jingmei Hsu, MD, Usama Gergis, MD MBA, Tsiporah B. Shore, MD, Sebastian Mayer, MD, Adrienne A. Phillips, MD MPH, Danielle Guarneri, BS, CCRP, Maria Baldo, PA, Ljiljana V. Vasovic, MD, Yen-Michael S. Hsu, MD PhD, Robert Andrew Desimone, MD, Melissa M. Cushing, MD, Koen Van Besien, MD PhD

Blood (2019) 134 (Supplement_1): 1169.

DOI: https://doi.org/10.1182/blood-2019-131306

Published: 2019

Journal Articles

Hemophagocytic Lymphohistiocytosis: A Single Institution Experience

Poornima Ramadas, MBBS, Jennifer Leibovitch, MD, Teresa Gentile, MD PhD

Blood (2019) 134 (Supplement_1): 4877.

DOI: https://doi.org/10.1182/blood-2019-127517

Published: 2019

Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 1558.

DOI: https://doi.org/10.1182/blood-2019-128945

Published: 2019

Journal Articles

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Muhamad Alhaj Moustafa, MD, Ricardo Parrondo, MD, Gregory Wiseman, MD, Jennifer Peterson, MD, Thomas E. Witzig, MD, Han W. Tun, MD

Blood (2019) 134 (Supplement_1): 1544.

DOI: https://doi.org/10.1182/blood-2019-130384

Published: 2019

Journal Articles

Beyond the Routine CBC: Research CBC Parameters Associated with Myelodysplastic Syndromes and Underlying Mutations

Olga Pozdnyakova, MD PhD, Radu Stefan Niculescu, PhD, Tracey Kroll, BSc, Lisa Golemme, MLS (ASCP), MS, Nolan Raymond, MLS (ASCP), Debra Briggs, MT(ASCP), MS, Annette S. Kim, MD PhD

Blood (2019) 134 (Supplement_1): 5419.

DOI: https://doi.org/10.1182/blood-2019-125654

Published: 2019

NARROW

Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy

Proton Pump Inhibitors Associated with Higher Incidence of Mucositis in Patients Receiving Methotrexate for Graft Vs Host Disease Prophylaxis

Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML)

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Choosing Wisely: Optimizing Outpatient Cancer Care and Conserving Resources with a New Algorithm to Report Automated ANC Results in the Presence of Analyzer Flags

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Inducible Expression of Mutant ELANE Correlates with Disruption of Differentiation Program, but Not the Unfolded Protein Response

A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2 -Mutated Myelodysplastic Syndromes (MDS)

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms

Evolution of Moderate Aplastic Anemia into Subclinical PNH/AA and Successful Treatment with Reduced Intensity Haplo-HSCT: A Pediatric Case Report

Effects of Hydroxyurea Treatment on Malaria Infections in Sub-Saharan Africa

Thirty-Day Transfusion and G-CSF Requirement after CD19 CAR T Infusion

Hemophagocytic Lymphohistiocytosis: A Single Institution Experience

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience

Beyond the Routine CBC: Research CBC Parameters Associated with Myelodysplastic Syndromes and Underlying Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only